Creart 0.25mg Injection
Marketer
Xyata Life Sciences Pvt Ltd
Salt Composition
Cetrorelix (0.25mg)
Overview Creart 0.25mg Injection
Ganirelix 0.25mg Injection, a gonadotropin-releasing hormone antagonist, treats female infertility. It prevents premature egg release, delaying ovulation. Administered subcutaneously by a healthcare professional, self-injection is contraindicated. Your doctor or nurse will instruct you on proper home injection technique. Dosage and frequency depend on your individual needs, determined by your physician to optimize treatment. Continue using the medication as prescribed. Common side effects include injection site reactions (redness, itching, swelling), nausea, and vomiting. Rotate injection sites daily (e.g., abdomen) to minimize irritation. Report dizziness, fainting, abdominal pain, or persistent vomiting immediately. Inform your physician of any pre-existing liver or kidney conditions, breastfeeding, or other medications you are currently using, as interactions may affect efficacy or alter the drug's action.
Uses of Creart 0.25mg Injection
Inability to conceive in women
Major Benefits of Creart 0.25mg Injection:
Administering this medication will be performed by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Creart 0.25mg Injection:
- Nausea
- Ovarian hyperstimulation syndrome
- Injection site reactions (pain, swelling, redness)
- Itching
- Irritation
- Vomiting
- Lower abdominal pain
How to use Creart 0.25mg Injection:
Administering this medication requires a healthcare professional (physician or nurse). Self-medication is strongly discouraged.
How Creart 0.25mg Injection works:
Premature egg release, a potential complication in infertility treatments for women, can result in ova unsuitable for fertilization. Creart 0.25mg Injection inhibits a naturally occurring hormone, thereby preventing this premature ovarian discharge.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Creart 0.25mg Injection alongside alcohol. Seek medical advice before combining them.
PregnancyUNSAFE
Administering Creart 0.25mg Injection during gestation presents a considerable risk. Pregnant individuals should consult their physician; research in animal models and human pregnancy indicates substantial potential harm to the fetus.
Breast feedingUNSAFE
Administering Creart 0.25mg Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingSAFE
Administering Creart 0.25mg Injection typically does not impair driving capabilities.
KidneyCAUTION
Exercise caution when administering Creart 0.25mg Injection to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Creart 0.25mg Injection is contraindicated in patients exhibiting severely compromised kidney function.
LiverCAUTION
Individuals with hepatic impairment should use Creart 0.25mg Injection cautiously. Dosage modification of Creart 0.25mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Creart 0.25mg Injection :
Omitting a scheduled dose of Creart 0.25mg Injection requires contacting your physician.
Facts to Know About Creart 0.25mg Injection
| Label | Value |
|---|---|
| Chemical Category | Amino acid chains |
| Developing Habits | No. |
| Treatment Category | Endocrine Signals |
| Behavior Class | GnRH receptor blockers |
3,018 People bought this recently